Press Releases

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
May 27, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics' CEO sells a small portion of his shareholding – remains a long-term major shareholder with strong confidence in the company’s future

Read more
May 22, 2025
2025
Press Release Non-regulatory

Elicera reports: Active lymphoma eliminated in two out of three patients in the first cohort of the CARMA study with iTANK-armed CAR T-cell therapy

Read more
May 15, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim 1 January – 31 March 2025

Regulatory
Read more
Apr 10, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics continues the Phase I/IIa CARMA study with its CAR T-cell therapy as planned following the safety committee’s assessment of cohort 1

Read more
Apr 4, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics' Chief Scientific Officer invited to speak at the Swedish Cancer Research Meeting 2025 on May 22

Read more
Mar 20, 2025
2025
Press Release Regulatory

Elicera Therapeutics resolves on a compensation issue to underwriters in connection with the completed exercise period for warrants of series TO2

Regulatory
Read more
Mar 13, 2025
2025
Press Release Regulatory

Warrants of series TO2 in Elicera Therapeutics AB were subscribed to approximately 96.3 percent and the company resolves on a directed issue to underwriters

Regulatory
Read more
Mar 7, 2025
2025
Press Release Regulatory

The last day of trading with the warrants of series TO2 in Elicera Therapeutics is today, March 7, 2025

Regulatory
Read more
Feb 28, 2025
2025
Press Release Non-regulatory

Correction: Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics

Read more
Feb 28, 2025
2025
Press Release Non-regulatory

Board members and the executive management exercise warrants of series TO2 in Elicera Therapeutics

Read more
Feb 25, 2025
2025
Press Release Regulatory

Elicera Therapeutics has secured 100 percent of the warrants of series TO2 corresponding to approximately SEK 22.0 million

Regulatory
Read more
Feb 25, 2025
2025
Press Release Regulatory

The exercise price for the warrants of series TO2 in Elicera Therapeutics has been determined to SEK 1.85

Regulatory
Read more
Feb 12, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics Receives Notification of Partial Payment of EUR 500,000 from the European Innovation Council Accelerator Programme

Read more
Feb 10, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics Presents Initial Clinical Data from the CARMA Study at ISCT 2025 in New Orleans

Read more
Feb 3, 2025
2025
Press Release Regulatory

Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2024

Regulatory
Read more
Jan 21, 2025
2025
Press Release Regulatory

Elicera Therapeutics presents first clinical results from iTANK-armed CAR T-cell therapy at scientific conference

Regulatory
Read more
Jan 13, 2025
2025
Press Release Non-regulatory

Elicera Therapeutics' drug candidate ELC-100 receives Orphan Drug Designation in the U.S. for the treatment of pancreatic neuroendocrine tumors

Read more
Nov 28, 2024
2024
Press Release Regulatory

Elicera Therapeutics AB (publ) Interim Report 1 January – 30 September 2024

Regulatory
Read more
Nov 5, 2024
2024
Press Release Non-regulatory

Elicera Therapeutics includes the first patient in the Phase I/II clinical study CARMA targeting B-cell lymphoma

Read more
Oct 24, 2024
2024
Press Release Non-regulatory

Elicera Therapeutics enrolls the last patient in the clinical phase I/II-trial with oncolytic virus ELC-100

Read more

Sign up for Press Releases

By filling out the form you are approving that Elicera stores your information. Read more about our integrity policy here.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
By continuing to browse this website you agree to cookies being stored on your device in order to improve the experience and analyze how it is being used. Read more in our Integrity policy.